LRRK2 and Parkinson disease: Notably, a recent study also reported that the VPS35 D620N mutation increases LRRK2 kinase activity in the mouse brain and that LRRK2 kinase inhibitors could correct D620N-dependent alterations in dopamine physiology, potentially linking these two familial PD genes (Bu et al., 2023).